Sii Investments Inc. WI Has $1.62 Million Position in Novo Nordisk A/S (NVO)
Sii Investments Inc. WI reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,654 shares of the company’s stock after selling 1,977 shares during the quarter. Sii Investments Inc. WI’s holdings in Novo Nordisk A/S were worth $1,617,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of NVO. Proficio Capital Partners LLC raised its stake in Novo Nordisk A/S by 155.6% during the 1st quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock valued at $103,000 after acquiring an additional 1,505 shares in the last quarter. AlphaMark Advisors LLC boosted its position in Novo Nordisk A/S by 1.1% during the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after acquiring an additional 30 shares during the period. Parallel Advisors LLC boosted its position in Novo Nordisk A/S by 120.3% during the 1st quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock worth $117,000 after acquiring an additional 1,553 shares during the period. MUFG Americas Holdings Corp boosted its position in Novo Nordisk A/S by 100.0% during the 2nd quarter. MUFG Americas Holdings Corp now owns 3,000 shares of the company’s stock worth $129,000 after acquiring an additional 1,500 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in shares of Novo Nordisk A/S by 167.8% in the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock worth $105,000 after purchasing an additional 1,918 shares in the last quarter. Hedge funds and other institutional investors own 6.01% of the company’s stock.
A number of research analysts have recently commented on the company. BidaskClub raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, June 15th. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Bank of America Corporation raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, September 6th. Finally, BNP Paribas lowered shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research report on Monday, September 25th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $55.00.
WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/04/sii-investments-inc-wi-has-1-62-million-position-in-novo-nordisk-as-nvo.html.
Shares of Novo Nordisk A/S (NYSE:NVO) traded up 0.63% during trading on Wednesday, reaching $49.37. The company’s stock had a trading volume of 625,061 shares. Novo Nordisk A/S has a 12 month low of $30.89 and a 12 month high of $49.45. The company has a market capitalization of $122.45 billion, a P/E ratio of 19.86 and a beta of 0.61. The company’s 50-day moving average is $47.54 and its 200-day moving average is $42.22.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.